|Bid||1.9900 x 0|
|Ask||2.0980 x 0|
|Day's range||1.8770 - 2.1000|
|52-week range||1.1000 - 46.7000|
|Beta (5Y monthly)||1.07|
|PE ratio (TTM)||N/A|
|Earnings date||20 Sept 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||108.00|
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
Orphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise.
Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.